Fig. 6From: Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancerComparison of ORR and DCR between irinotecan combined cytotoxic chemotherapy versus irinotecan monotherapyBack to article page
